Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-05-09
2006-05-09
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S085200, C424S198100, C424S278100, C514S885000
Reexamination Certificate
active
07041294
ABSTRACT:
A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1α(IL-1α) and interleukin-1β (IL-1β).
REFERENCES:
patent: 4935343 (1990-06-01), Allison et al.
patent: 5008374 (1991-04-01), Nakai et al.
patent: 5206014 (1993-04-01), Nencioni et al.
patent: 5210072 (1993-05-01), Chedid et al.
patent: 5266311 (1993-11-01), Cerreti et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5342614 (1994-08-01), Nakai et al.
patent: 5342615 (1994-08-01), Nakai et al.
patent: 5371204 (1994-12-01), Nakai et al.
patent: 5437988 (1995-08-01), Bellini et al.
patent: 5474899 (1995-12-01), Lisi
patent: 5543140 (1996-08-01), Nakai et al.
patent: 5702698 (1997-12-01), Nakai et al.
patent: 5728571 (1998-03-01), Velati Bellini et al.
patent: 6153182 (2000-11-01), Lillard, Jr.
patent: 6656462 (2003-12-01), Dondero et al.
patent: 353516 (1994-09-01), None
patent: 761688 (1997-03-01), None
patent: 810285 (1997-12-01), None
patent: 63-258595 (1988-10-01), None
patent: 05-244990 (1993-09-01), None
patent: 93/01929 (1994-10-01), None
patent: WO 88/06843 (1988-09-01), None
patent: WO 91/01143 (1991-02-01), None
patent: WO 91/13986 (1991-09-01), None
patent: WO 92/03574 (1992-03-01), None
patent: WO 94/00491 (1994-01-01), None
patent: WO 96/07673 (1996-03-01), None
Kramer et al., “Cytokine Mediated Effects in Mucosal Immunity”, vol. 73, Immunology and Cell Biology, pp. 389-396 (1995).
Nash et al., “Recombinant Cytokines as Immunological Adjuvants”, vol. 71, Immunology and Cell Biology, pp. 367-379 (1993).
Lin et al., “Present Status of the Use of Cytokines as Adjuvants with Vaccines to Protect Against Infectious Diseases”, vol. 21, Clinical Infectious Diseases, pp. 1439-1449 (1995).
Lin et al., “Nasal Tolerance to Experimental Autoimmune Myasthenia Gravis: Tolerance Reversal by Nasal Administration of Minute Amounts of Interferon- ”, vol. 87 Clinical Immunology and Immunopathology, pp. 15-22 (1998).
Marinaro et al., “Oral but Not Parenteral Interleukin (IL)-12 Redirects T Helper2 (Th2)-type Responses to an Oral Vaccine Without Altering Mucosal IgA Responses”, vol. 185, No. 3, J Exp. Med., pp. 415-427 (Feb. 3, 1997).
Xiao et al., “Suppression of Acute and Protracted-relapsing Experimental Allergic Encephalomyelitis by Nasal Administration of Low-dose IL-10 in Rats”, vol. 84, Journal of Neuroimmunology, pp. 230-237 (Apr. 15, 1998) (Abstract).
Fujimara et al., “Effect of Thromboxane A2 Antagonists on Bronchial Hyperresponsiveness Induced Immediately after Interleukin-8 Inhalation in Guinea-pigs”, vol. 122, British Journal of Pharmacology, pp. 1015-1020 (1997).
Callard et al., “The Cytokine Facts Book”, Academic Press, Harcourt and Co., Publishers, pp. 241 (1994).
Abraham et al., “Intranasal Immunization with Liposomes Containing IL-2 Enhances Bacterial Polysaccharide Antigen-Specific Pulmonary Antibody Response”, Journal of Immunology, vol. 149, No. 11, pp. 3719-3726 (1992).
Gao et al., “BHV-1 Glycoprotein 1 and Recombinant Interleukin 1B Efficiently Elicit Mucosal IgA Response”, Vaccine, vol. 13, No. 9, pp. 871-877 (1995).
Sarkar, “Drug Metabolism in the Nasal Mucosa,” Pharm. Res., p. 1-9, (1992).
Pontiroli et al., “Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: A Comparison of Powders and Spray Solutions and of Different Enhancing Agents,” European Journal of Clinical Pharmocology, p. 427-430, (1989).
Elson et al., “Mucosal Adjuvants,” Handbook of Mucosal Immunology, Academic Press, Inc. (San Diego), p. 391-402, (1994).
Reiss, T. and Strauss, E., “Vaccines-Patenting Dynamics of a Powerful Healthcare Tool,” Exp. Opin. Ther. Patents, vol. 8 (No. 8), p. 951-958, (1998).
Elson, “Cholera Toxin as a Mucosal Adjuvant,” Mucosal Vaccines, Academic Press (New York), p. 59-72, (1996).
Jenkins, “Mucosal Vaccine Delivery,” Exp. Opin. Ther. Patents, p. 255-262, (1999).
Lillard et al., “Lymphotactin Acts as an Innate Mucosal Adjuvant,” J. Immuno., vol. 162, (No.4), p. 1959-1965, (1999).
MRSNY, “Adjuvants and Delivery Issues Related to Immunization: A Survey of the Recent Patent Literature,” J. of Drug Targeting, vol. 6 (No. 4), p. 243-249, (1998).
Giannarini et al.., “Decrease of Allergen-specific T-cell Response Induced by Local Nasal Immunotherapy”, vol. 28, Clinical and Experimental Allergy, pp. 404-412 (1998).
Pockley et al., “In Vivo Adjuvant Effect of Interleukins 5 and 6 on Rat Tear IgA Antibody Responses”, vol. 73, Immunology, pp. 19-23 (1991).
O'Hagan, “Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration”, vol. 49, J. Pharm. Pharmacol, pp. 1-10 (1997).
Staats et al.,IL -1 is an Effective Adjuvant for Muscosal and Systemic Immune Responses When co administered with Protein Immungens, The American Associtation of Immunologists, 162: 6141-6147 (1999).
Hazama et al.,Intranasal immunization against herpes simplex virus infection by using a recombiant glycoprotein D fused with immunodulating proteins, the B subunit of Eschericha coli heat-labile enterotoxin and interleukin-2, Immunology 78: 643-649 (1993).
Sasaki,Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency virus Ttpe 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via intramuscular and Intranasal Routes, Journal of Virology, 72 (6): 4931-4939 (1998).
Haynes Barton F.
Patel Dhavalkumar D.
Sempowski Gregory D.
Staats Herman F.
Duke University
Jenkins & Wilson & Taylor, P.A.
Landsman Robert
LandOfFree
Substantially non-toxic biologically active mucosal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substantially non-toxic biologically active mucosal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substantially non-toxic biologically active mucosal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587245